Wedbush Predicts Weaker Earnings for Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Stock analysts at Wedbush decreased their FY2025 earnings estimates for Xenon Pharmaceuticals in a report released on Tuesday, November 4th. Wedbush analyst L. Chico now forecasts that the biopharmaceutical company will earn ($4.04) per share for the year, down from their prior estimate of ($3.87). Wedbush has a “Outperform” rating and a $43.00 price objective on the stock. The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.10) per share. Wedbush also issued estimates for Xenon Pharmaceuticals’ Q2 2026 earnings at ($0.95) EPS, Q3 2026 earnings at ($1.01) EPS, FY2026 earnings at ($3.95) EPS and FY2027 earnings at ($3.62) EPS.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported ($1.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.01. The firm’s quarterly revenue was up .0% on a year-over-year basis. During the same quarter last year, the firm earned ($0.81) EPS.

A number of other equities research analysts have also recently commented on the stock. Wells Fargo & Company reiterated an “overweight” rating and issued a $44.00 target price (down from $48.00) on shares of Xenon Pharmaceuticals in a research report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research report on Tuesday, October 14th. Royal Bank Of Canada increased their target price on shares of Xenon Pharmaceuticals from $55.00 to $58.00 and gave the company an “outperform” rating in a research report on Tuesday. Cantor Fitzgerald reiterated an “overweight” rating and issued a $55.00 target price on shares of Xenon Pharmaceuticals in a research report on Tuesday. Finally, Chardan Capital reiterated a “buy” rating and issued a $55.00 target price on shares of Xenon Pharmaceuticals in a research report on Tuesday, October 7th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Xenon Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $53.70.

Xenon Pharmaceuticals Stock Performance

NASDAQ:XENE opened at $38.66 on Thursday. The company has a fifty day moving average of $39.40 and a two-hundred day moving average of $35.43. The stock has a market capitalization of $2.98 billion, a PE ratio of -10.89 and a beta of 1.10. Xenon Pharmaceuticals has a fifty-two week low of $26.74 and a fifty-two week high of $46.00.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Farther Finance Advisors LLC purchased a new position in Xenon Pharmaceuticals during the second quarter worth about $25,000. Caitong International Asset Management Co. Ltd purchased a new position in Xenon Pharmaceuticals during the first quarter worth about $30,000. Elevation Point Wealth Partners LLC purchased a new position in Xenon Pharmaceuticals during the second quarter worth about $32,000. Osaic Holdings Inc. boosted its stake in Xenon Pharmaceuticals by 541.4% during the second quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 1,034 shares during the period. Finally, L1 Capital Pty Ltd purchased a new position in Xenon Pharmaceuticals during the second quarter worth about $41,000. Hedge funds and other institutional investors own 95.45% of the company’s stock.

Insider Activity

In related news, CEO Ian Mortimer sold 25,000 shares of the company’s stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $40.16, for a total value of $1,004,000.00. Following the completion of the sale, the chief executive officer owned 31,302 shares of the company’s stock, valued at approximately $1,257,088.32. This represents a 44.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 4.07% of the company’s stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.